Despite the novel agents currently available for T2D, the percentage of patients who are candidates for insulin treatment is expected to increase over the following decades due to the extension of life expectancy and the absolute increase in the number of patients living with T2D. The gene discussed is INS; the disease is type 2 diabetes mellitus.